Skip to main content

View full-text article in PMC

. 2021 Mar 4;13(1):1884516. doi: 10.1080/19490976.2021.1884516

Table 5.

Relationship between TcdB/CDT and severe disease, complications and recurrence

		TcdB			CDT			TcdB/CDT
		TcdB+	TcdB-	p-value	CDT+	CDT-	p-value	TcdB+/CDT+	TcdB-/CDT+	TcdB+/CDT-	TcdB-/CDT-	p-value
Severe disease^c n (%)	Yes	29 (35.4)	31²⁰	0.048^a	29 (39.2)	29 (21.2)	0.005^a	15 (45.5)	13 (34.2)	11 (27.5)	18 (18.6)	0.018^a
Severe disease^c n (%)	No	82 (64.5)	135 (77)	0.048^a	74 (60.8)	137 (78.8)	0.005^a	18 (54.5)	25 (65.8)	29 (72.5)	79 (81.4)	0.018^a
Complications n (%)	Yes	17 (20.7)	15 (11.5)	0.053^a	16 (21.6)	15 (10.9)	0.037^a	11 (33.3)	5 (13.2)	5 (12.5)	10 (10.3)	0.013^a
Complications n (%)	No	82 (79.3)	135 (88.5)	0.053^a	74 (78.4)	137 (89.1)	0.037^a	22 (66.7)	33 (86.8)	35 (87.5)	87 (89.7)	0.013^a
Recurrence n (%)	Yes	12 (14.6)	8 (5.9)	0.032^a	11 (14.9)	8 (5.8)	0.028^a	8 (24.2)	3 (7.9)	3 (7.5)	5 (5.2)	0.031^b
Recurrence n (%)	No	82 (85.4)	135 (94.1)	0.032^a	74 (85.1)	137 (94.2)	0.028^a	25 (75.8)	35 (92.1)	37 (92.5)	92 (94.8)	0.031^b

^aPearson’s Chi-square; ^bLikelihood ratio; ^c ZAR score